These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11377484)

  • 1. Trough level-guided mycophenolate mofetil rejection prophylaxis in liver transplantation.
    Grasser B; Iberer F; Schaffellner S; Kniepeiss D; Stauber R; Koshsorur G; Rehak P; Tscheliessnigg KH
    Transplant Proc; 2001 May; 33(3):2154-6. PubMed ID: 11377484
    [No Abstract]   [Full Text] [Related]  

  • 2. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage.
    Bahra M; Neumann UP; Harren M; Jacob D; Langrehr JM; Berg T; Neuhaus R; Neuhaus P
    Transplant Proc; 2002 Nov; 34(7):2934-5. PubMed ID: 12431663
    [No Abstract]   [Full Text] [Related]  

  • 3. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
    Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
    Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy of mycophenolate mofetil treatment in the prevention of acute renal rejection is related to plasma level of mycophenolic acid.
    Kuriata-Kordek M; Boratyńska M; Klinger M; Woźniak M; Urbaniak J; Szyber P; Patrzalek D; Tupka D
    Transplant Proc; 2002 Nov; 34(7):2985-7. PubMed ID: 12431678
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring of anti-rejection therapy by serum bile acids after liver transplantation.
    Klar E; Theilmann L; Hoffmann V; Hofmann W; Kraus T; Mehrabi A; Herfarth C
    Transplant Proc; 1998 Nov; 30(7):3567-9. PubMed ID: 9838562
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic drug level monitoring for mycophenolate mofetil: is it justified?
    Stephan A; Masri MA; Barbari A; Kamel G; Karam A; Kilani H
    Transplant Proc; 2001 Aug; 33(5):2778-9. PubMed ID: 11498157
    [No Abstract]   [Full Text] [Related]  

  • 7. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.
    Meiser BM; Pfeiffer M; Schmidt D; Ueberfuhr P; Reichenspurner H; Paulus D; von Scheidt W; Kreuzer E; Seidel D; Reichart B
    Transplant Proc; 1999; 31(1-2):84-7. PubMed ID: 10083018
    [No Abstract]   [Full Text] [Related]  

  • 8. Mycophenolate: better value through monitoring?
    Tredger JM; Brown NW
    Transplantation; 2006 Feb; 81(4):507-8. PubMed ID: 16495794
    [No Abstract]   [Full Text] [Related]  

  • 9. Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation.
    Platz KP; Mueller AR; Willimski C; Mansoorian B; Berg T; Neuhaus R; Hopf U; Radke C; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2232-3. PubMed ID: 9723453
    [No Abstract]   [Full Text] [Related]  

  • 10. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.
    Nicholls AJ
    Clin Biochem; 1998 Jul; 31(5):329-33. PubMed ID: 9721430
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J
    Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449
    [No Abstract]   [Full Text] [Related]  

  • 14. Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral.
    Levy GA
    Transplant Proc; 1996 Aug; 28(4):2252-3. PubMed ID: 8769216
    [No Abstract]   [Full Text] [Related]  

  • 15. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite.
    Shipkova M; Schütz E; Armstrong VW; Niedmann PD; Wieland E; Oellerich M
    Transplant Proc; 1999; 31(1-2):1135-7. PubMed ID: 10083508
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-T-cell-antibody prophylaxis in children: success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum.
    Boucek MM; Pietra B; Sondheimer H; Luna M; Shaffer E; Hall P; Campbell D
    Transplant Proc; 1997 Dec; 29(8A):16S-20S. PubMed ID: 9414669
    [No Abstract]   [Full Text] [Related]  

  • 17. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.
    Klupp J; Glanemann M; Bechstein WO; Platz KP; Langrehr JM; Keck H; Settmacher U; Radtke C; Neuhaus R; Neuhaus P
    Transplant Proc; 1999; 31(1-2):1113-4. PubMed ID: 10083497
    [No Abstract]   [Full Text] [Related]  

  • 18. How to handle mycophenolate mofetil in combination with tacrolimus?
    Braun F; Canelo R; Schütz E; Shipkora M; Lorf T; Hanack U; Niedmann D; Armstrong VW; Oellerich M; Ringe B
    Transplant Proc; 1998 Dec; 30(8):4094-5. PubMed ID: 9865309
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial.
    Sterneck M; Fischer L; Gahlemann C; Gundlach M; Rogiers X; Broelsch C
    Ann Transplant; 2000; 5(1):43-6. PubMed ID: 10850611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites.
    Schütz E; Shipkova M; Armstrong VW; Niedmann PD; Weber L; Tönshoff B; Pethig K; Wahlers T; Braun F; Ringe B; Oellerich M
    Transplant Proc; 1998 Jun; 30(4):1185-7. PubMed ID: 9636479
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.